2020
Automated feature quantification of Lipiodol as imaging biomarker to predict therapeutic efficacy of conventional transarterial chemoembolization of liver cancer
Stark S, Wang C, Savic LJ, Letzen B, Schobert I, Miszczuk M, Murali N, Oestmann P, Gebauer B, Lin M, Duncan J, Schlachter T, Chapiro J. Automated feature quantification of Lipiodol as imaging biomarker to predict therapeutic efficacy of conventional transarterial chemoembolization of liver cancer. Scientific Reports 2020, 10: 18026. PMID: 33093524, PMCID: PMC7582153, DOI: 10.1038/s41598-020-75120-7.Peer-Reviewed Original ResearchConceptsConventional transarterial chemoembolizationLipiodol depositionTransarterial chemoembolizationLiver cancerPeripheral depositionLipiodol depositsTherapeutic efficacyNecrotic tumor areasBaseline MRITherapy optionsTumor responseTreatment responseTumor volumeLiver lesionsLipiodolH postTumor areaH-CTHounsfield unitsBiomarkersChemoembolizationHigh rateTumorsCancerImproved response
2014
Systemic Delivery of Microencapsulated 3-Bromopyruvate for the Therapy of Pancreatic Cancer
Chapiro J, Sur S, Savic LJ, Ganapathy-Kanniappan S, Reyes J, Duran R, Thiruganasambandam SC, Moats CR, Lin M, Luo W, Tran PT, Herman JM, Semenza GL, Ewald AJ, Vogelstein B, Geschwind JF. Systemic Delivery of Microencapsulated 3-Bromopyruvate for the Therapy of Pancreatic Cancer. Clinical Cancer Research 2014, 20: 6406-6417. PMID: 25326230, PMCID: PMC4300523, DOI: 10.1158/1078-0432.ccr-14-1271.Peer-Reviewed Original ResearchConceptsPancreatic ductal adenocarcinomaSuit-2 cell lineOrthotopic xenograft mouse modelBioluminescence imagingFavorable toxicity profileSublethal drug concentrationsAnti-invasive effectsXenograft mouse modelPDAC cell linesCell linesXenograft tumor modelHalf maximal inhibitory concentrationStrong anticancer effectsPancreatic cancerClinical trialsDuctal adenocarcinomaMouse modelToxicity profileIC50 profileTherapeutic efficacyMatrigel invasionVivo efficacyBLI signalMatrigel assaysMiaPaCa-2